These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 35644668)

  • 1. Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB).
    Sassaki LY; Magro DO; Saad-Hossne R; Baima JP; Flores C; Correia LM; Celani LMS; De Abreu Ferrari ML; Zacharias P; Feitosa MR; Dos Santos CHM; De Freitas Lins Neto MA; Quaresma AB; De Lima Junior SF; De Vasconcelos GBS; Cassol OS; Dos Santos Pinto A; Kurachi G; Goncalves Filho FA; Gasparini RG; Furlan TK; Catapani WR; Coy CSR; De Souza Menegassi V; Colombo MM; Fróes RSB; Teixeira FV; Moraes AC; Santana GO; Parente JML; Vilela EG; Queiroz NSF; Kotze PG;
    BMC Gastroenterol; 2022 May; 22(1):268. PubMed ID: 35644668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis.
    Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
    Aliment Pharmacol Ther; 2016 May; 43(9):994-1003. PubMed ID: 26991059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab.
    Favale A; Onali S; Caprioli F; Pugliese D; Armuzzi A; Macaluso FS; Orlando A; Viola A; Fries W; Rispo A; Castiglione F; Mocci G; Chicco F; Usai P; Calabrese E; Biancone L; Monteleone G; Fantini MC;
    Inflamm Bowel Dis; 2019 Oct; 25(11):1805-1812. PubMed ID: 30931477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. INFLIXIMAB AND ADALIMUMAB SERUM TROUGH CONCENTRATIONS THRESHOLD ASSOCIATED WITH DEEP REMISSION IN INFLAMMATORY BOWEL DISEASE.
    Pascual-Marmaneu Ó; Belles-Medall MD; Ferrando-Piqueres R; Almela-Notari P; Mendoza-Aguilera M; Álvarez-Martín T
    Farm Hosp; 2021 Aug; 45(5):225-233. PubMed ID: 34806581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study.
    Barberio B; Zingone F; D'Incà R; Rovigo L; Bertani L; Bodini G; Ghisa M; Gubbiotti A; Massimi D; Lorenzon G; Savarino EV
    Clin Transl Gastroenterol; 2020 May; 11(5):e00177. PubMed ID: 32677808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study.
    Christensen KR; Steenholdt C; Brynskov J
    Scand J Gastroenterol; 2015 Aug; 50(8):1018-24. PubMed ID: 25861832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-Life Comparison of Different Anti-TNF Biologic Therapies for Ulcerative Colitis Treatment: A Retrospective Cohort Study.
    Barberio B; Zingone F; Frazzoni L; D'Incà R; Maccarone MC; Ghisa M; Massimi D; Lorenzon G; Savarino EV
    Dig Dis; 2021; 39(1):16-24. PubMed ID: 32450562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term follow-up of inflammatory bowel disease patients receiving anti-tumor necrosis factor-alpha therapy].
    Bacsur P; Skribanek S; Milassin Á; Farkas K; Bor R; Fábián A; Rutka M; Bálint A; Szántó KJ; Tóth T; Nagy F; Szepes Z; Boda K; Molnár T
    Orv Hetil; 2020 Nov; 161(47):1989-1994. PubMed ID: 33226355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study.
    Hupé M; Rivière P; Nancey S; Roblin X; Altwegg R; Filippi J; Fumery M; Bouguen G; Peyrin-Biroulet L; Bourreille A; Caillo L; Simon M; Goutorbe F; Laharie D
    Aliment Pharmacol Ther; 2020 May; 51(9):852-860. PubMed ID: 32201971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
    Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
    Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.
    Iborra M; Pérez-Gisbert J; Bosca-Watts MM; López-García A; García-Sánchez V; López-Sanromán A; Hinojosa E; Márquez L; García-López S; Chaparro M; Aceituno M; Calafat M; Guardiola J; Belloc B; Ber Y; Bujanda L; Beltrán B; Rodríguez-Gutiérrez C; Barrio J; Cabriada JL; Rivero M; Camargo R; van Domselaar M; Villoria A; Schuterman HS; Hervás D; Nos P;
    J Gastroenterol; 2017 Jul; 52(7):788-799. PubMed ID: 27722996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource.
    Kapizioni C; Desoki R; Lam D; Balendran K; Al-Sulais E; Subramanian S; Rimmer JE; De La Revilla Negro J; Pavey H; Pele L; Brooks J; Moran GW; Irving PM; Limdi JK; Lamb CA; ; Parkes M; Raine T
    J Crohns Colitis; 2024 Jun; 18(6):790-800. PubMed ID: 38041850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study.
    Han M; Jung YS; Cheon JH; Park S
    Yonsei Med J; 2020 Jan; 61(1):48-55. PubMed ID: 31887799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study.
    Viola A; Pugliese D; Renna S; Furfaro F; Caprioli F; D'Incà R; Bossa F; Mazza S; Costantino G; Fantini MC; Fiorino G; Alibrandi A; Orlando A; Armuzzi A; Fries W
    Dig Liver Dis; 2019 Apr; 51(4):510-515. PubMed ID: 30472389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment.
    Lee SH; Walshe M; Oh EH; Hwang SW; Park SH; Yang DH; Byeon JS; Myung SJ; Yang SK; Greener T; Weizman AV; Silverberg MS; Ye BD
    Inflamm Bowel Dis; 2021 Aug; 27(9):1452-1461. PubMed ID: 33269403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Adalimumab in Pediatric Ulcerative Colitis: A Real-life Experience from the SIGENP-IBD Registry.
    Aloi M; Bramuzzo M; Arrigo S; Romano C; D'Arcangelo G; Lacorte D; Gatti S; Illiceto MT; Zucconi F; Dilillo D; Zuin G; Knafelz D; Ravelli A; Cucchiara S; Alvisi P;
    J Pediatr Gastroenterol Nutr; 2018 Jun; 66(6):920-925. PubMed ID: 29315163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice.
    Bálint A; Farkas K; Palatka K; Lakner L; Miheller P; Rácz I; Hegede G; Vincze Á; Horváth G; Szabó A; Nagy F; Szepes Z; Gábor Z; Zsigmond F; Zsóri Á; Juhász M; Csontos Á; Szűcs M; Bor R; Milassin Á; Rutka M; Molnár T
    J Crohns Colitis; 2016 Jan; 10(1):26-30. PubMed ID: 26392413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.
    Sandborn WJ; Sakuraba A; Wang A; Macaulay D; Reichmann W; Wang S; Chao J; Skup M
    Curr Med Res Opin; 2016 Jul; 32(7):1233-41. PubMed ID: 26986449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful use of golimumab in a patient with ulcerative colitis refractory to infliximab and adalimumab.
    Cortes X; Borrás-Blasco J; Flor L; Antequera B; Fernandez-Martinez S; Molés JR; Casterá E
    Int J Clin Pharmacol Ther; 2021 Mar; 59(3):257-260. PubMed ID: 33261721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
    Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
    Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.